mRNA Cancer Vaccines: The Personalised Revolution
"Nearly 90% of the patients whose immune systems responded to the vaccine are still alive six years later. For pancreatic cancer, that is not a result we ever expected to see.
"Dr. Vinod Balachandran
A New Kind of Vaccine
Traditional vaccines teach your immune system to recognise a specific, shared target, such as a viral protein. mRNA cancer vaccines do something fundamentally different: they are built from a biopsy of your own tumour. Scientists sequence the DNA, identify the mutations unique to your cancer, and encode up to 34 of those targets into a custom mRNA strand. Injected into your arm, it trains your immune cells to hunt down cells carrying those exact mutations. No two patients receive the same vaccine. The technology was always theoretically possible but practically out of reach. The COVID-19 pandemic changed that. Moderna and BioNTech, forced to manufacture billions of mRNA doses at speed, built the industrial infrastructure that now makes personalised cancer vaccines manufacturable in roughly six weeks per patient. The same lipid nanoparticle delivery system that carried COVID spike protein into cells now carries tumour-specific neoantigens to the immune system.
subtitle: The 2026 cancer pipeline: where each stands
[icon:CHECK] Melanoma (Moderna / mRNA-4157 + Keytruda): Phase 3 INTerpath-001 ongoing. Phase 2b showed 49% lower risk of recurrence or death and 62% lower risk of distant metastasis vs Keytruda alone. Regulatory submission from Moderna expected in 2026.
[icon:CHECK] Pancreatic cancer (BioNTech / BNT122 + Keytruda): Phase 2 IMCODE003 ongoing. Phase 1 six-year follow-up (AACR 2026): of 8 immune responders, 6 remain alive. Five-year pancreatic survival rate is normally around 13%.
[icon:CHECK] Non-small-cell lung cancer (Moderna / mRNA-4157 + Keytruda): Phase 3 INTerpath-002 underway in resected NSCLC (stages IB to IIIA). First readout expected late 2026 to 2027.
[icon:CHECK] Colorectal cancer (multiple): KRAS-targeted mRNA vaccines in Phase 2. KRAS mutations drive roughly 40% of colorectal cancers and have resisted targeted therapy for 40 years.
[icon:CHECK] Glioblastoma (brain tumour): first-in-human mRNA vaccine trial completed. An mRNA approach that reprogrammed the immune system to treat this aggressive brain tumour showed measurable response in the early human cohort, published July 2026.
[icon:CHECK] Breast, bladder, kidney, head and neck cancers: early Phase 1 or Phase 2 trials active across Moderna, BioNTech, Gritstone Bio, and several academic centres.
[icon:CLOCK] Regulatory milestone watch: if INTerpath-001 (melanoma) reads out positive, it would be the first Phase 3 approval of any personalised cancer vaccine in history.
Reduction in melanoma recurrence or death (Phase 2b)
49% lower vs immunotherapy alone
Pancreatic cancer responders alive at 6 years (Phase 1)
approximately 90%
Active clinical trials using mRNA cancer vaccines (2026)
more than 120 worldwide
Tumour mutations encoded per personalised vaccine
up to 34 neoantigens per patient
Time to manufacture a personalised vaccine from biopsy
approximately 6 weeks
Forecast peak sales for mRNA-4157 V940 (GlobalData, 2031)
$2.3 billion annually
Normal 5-year survival for pancreatic cancer
approximately 13%
How the manufacturing works. After surgical removal of a tumour, a sample is sent to Moderna or BioNTech's facility. The tumour's DNA is fully sequenced, then compared against the patient's healthy DNA to identify somatic mutations that exist only in the cancer cells. A proprietary algorithm ranks those mutations by immunogenicity: how likely each is to trigger a T-cell response. The top candidates, up to 34, are encoded into an mRNA sequence, synthesised, encapsulated in lipid nanoparticles, an
Is personalised cancer vaccination the future of oncology, or is the hype ahead of the data?
The Phase 2b melanoma data and the six-year pancreatic survival figures are remarkable. But Phase 3 results have not yet read out, the approach costs hundreds of thousands of dollars per patient, and six weeks of manufacturing time is not viable for fast-growing tumours. Is this a genuine revolution in cancer treatment, or a targeted benefit for a narrow group of patients who can access it?
What happens next. Moderna expects to submit mRNA-4157 (V940) for regulatory approval in melanoma in 2026, with FDA review expected to take 12 months. A positive verdict in melanoma would likely accelerate approvals across lung, colorectal, and other tumour types. BioNTech has said it expects to publish Phase 2 pancreatic data in 2026 to 2027. The first approval, if it comes, will unlock reimbursement negotiations in the US, EU, UK, and Japan simultaneously, setting the price that determines whe
